MetaCap

TG Therapeutics Inc. (TGTX)

NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

63.34-1.54 (-2.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TGTX stock chart

Technical analysis

Key statistics

All statistics
52-week range
26.76 – 68.03
Day range
63.12 – 65.64
Volume / Avg
2.09M / 1.86M
Beta
—

52-week range

$26.76$68.03

TGTX stock today

On Nov 20, TGTX ended the session at $63.34, shedding $1.54 (2.37%), versus the S&P 500's 3.70% decline. Shares are 6.9% below their 52-week high of $68.03, set on Nov 10, 2026 and 136.7% above the 52-week low of $26.76, near the top of the past year's range. TGTX is up 112.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 98.2%.

TG Therapeutics trades at 94.5x its trailing twelve-month earnings per share of $0.67. Its forward P/E of 24.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About TG Therapeutics

Company profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Michael S. Weiss Esq., J.D.
Headquarters
Morrisville, NC
Employees
399

Financial highlights

Full financials

In fiscal 2025, TG Therapeutics generated $616.3 million in revenue, up 87.3% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $447.2 million (+1812.4% year over year), for a net margin of 72.6% versus a median of -5204.1% in the prior 5 years. Gross margin was 83.7% (down from 88.3%) and operating margin 20.0%.

TG Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$616.29M$329.00M$233.66M$2.79M$6.69M
Growth+87.32%+40.80%+8290.02%-58.36%+4300.66%
Net income$447.18M$23.38M$12.67M$-223.81M$-348.10M
EPS (diluted)$2.77$0.15$0.09$-1.65$-2.63

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$69.43+9.61%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 1

Target range

Low $21.00High $86.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$2.43 vs $0.28
Surprise
+767.86%

TGTX news

All TGTX news

TG Therapeutics peers

Health Care sector
TGTX peer companies
CompanyPrice% ChgMarket capCompare
SYRESpyre Therapeutics Inc.93.47-4.26%$8.88Bvs TGTX
MDGLMadrigal Pharmaceuticals Inc.379.10-4.45%$8.81Bvs TGTX
PRAXPraxis Precision Medicines Inc.300.43-3.37%$8.40Bvs TGTX
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs TGTX
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs TGTX
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs TGTX
ALKSAlkermes plc44.94-2.69%$7.55Bvs TGTX
BMRNBioMarin Pharmaceutical Inc.60.41-1.64%$11.70Bvs TGTX

Indexes, lists and sector

TG Therapeutics stock FAQ

What is TG Therapeutics's stock price today?

TGTX last traded at $63.34 as of Nov 20, 4:00 PM EST, down 2.37% on the day. Prices are delayed at least 15 minutes.

Does TG Therapeutics pay a dividend?

No. TG Therapeutics does not currently pay a regular cash dividend.

What is TGTX's P/E ratio?

TGTX trades at a trailing P/E ratio of 94.54 and a forward P/E of 24.81.

Who is TG Therapeutics's CEO?

Mr. Michael S. Weiss Esq., J.D. is the chief executive officer of TG Therapeutics Inc., which has about 399 employees.

Has TGTX ever split its stock?

Yes. The most recent TGTX stock split was a 100-for-5625 split on Apr 30, 2012, one of 2 splits on record.

What is the TGTX 52-week high?

The 52-week high for TGTX is $68.03 and the 52-week low is $26.76. The stock is currently 6.9% below its high.

Compare TGTX